One Year Clinical Outcomes in Patients With Coronary Bifurcation Lesions: Results From the Resolute Onyx Bifurcation Study

Price, Matthew; Boutis, Loukas; Kirtane, Ajay J.; Chetcuti, Stanley; Poliačiková, Petra; Dens, Joseph; Attubato, Michael; Ya-le, Wang; Hu, Patrick; Spriggs, Douglas; Krasnow, Joshua; Chatzizisis, Yiannis S.; Aminian, Adel; Shah, Alpesh; Dauler, Michelle; Ibrahim, Sherif; Lung, Te-Hsin; Sánchez, Oscar D.; Mehran, Roxana

doi:10.1016/s0735-1097(21)02324-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the absence of device-to-device comparative data, in September of 2022, the Food and Drug Administration (FDA) cleared Resolute Onyx Frontier (Medtronic, Minneapolis, MN, United States) as first DES to receive indication for non-LM bifurcation PCI based on data from the Resolute Bifurcation Study [ 35 ]. Resolute Onyx Frontier DES demonstrated low event rates, achieving the performance goal for the primary endpoint of target vessel failure (TVF) at one year [ 36 ]. In a total of 205 patients with 207 bifurcation lesions among which 32.4% of lesions were classified to be true bifurcation lesions with disease of the SB, the rate of the primary endpoint of TVF at 1 year was 6.9% with a 1-sided upper 95% confidence interval of 10.5%, significantly lower than the pre-specified performance goal ( p

0.001).…”

Section: Clinical Datamentioning

confidence: 99%

DES Selection for Left Main and Coronary Bifurcation Stenting

Mehmedbegović,

Jelić,

Mladenović

et al. 2023

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Coronary bifurcation lesions present a challenging lesion subset regarding procedural complexity and worse patient outcomes as compared to simple lesions. Drug eluting stents (DES), as the current standard of care for percutaneous myocardial revascularization, have tubular design and uniform diameter, and therefore, need to be subjected to a standardized set of procedural modifications, to optimally fit and reconstruct underlying bifurcation anatomy. Since contemporary DES have various design platforms, with diverse mechanical properties, we must be aware of the device’s favorable characteristics and limitations, to ensure maximal procedural safety and success. This is especially true for bifurcation lesion stenting, during which device integrity will often be eventually tested by undergoing specific procedural steps, such as proximal balloon optimization, kissing-balloon inflations, or even intentional stent crushing. In this review we address the design characteristics of contemporary DES, their bifurcation-specific experimental testing data, and reported clinical results, in an attempt to provide relevant information and help in device selection for bifurcation stenting procedures.

show abstract

0.001).…”

Section: Clinical Datamentioning

confidence: 99%